MPTP-induced neuroblast apoptosis in the subventricular zone is not regulated by dopamine or other monoamine transporters

NeuroToxicology

Volumn 30, Issue 6, 2009, Pages 1036-1044

  Shibui, Yusuke ^a   He, Xi Jun ^a   Uchida, Kazuyuki ^a   Nakayama, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Apoptosis; Dopamine transporter; Monoamine transporter; MPTP; Neuroblast

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DESIPRAMINE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOPAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; TETRABENAZINE; URIDINE TRIPHOSPHATE; VANOXERINE; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NERVE CELL NECROSIS; NEUROBLAST; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SUBVENTRICULAR ZONE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC UPTAKE INHIBITORS; ADULT STEM CELLS; ANIMALS; APOPTOSIS; CEREBRAL VENTRICLES; DESIPRAMINE; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; FLUOXETINE; GENE EXPRESSION REGULATION; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; NEUROTOXINS; NEUROTRANSMITTER TRANSPORT PROTEINS; PIPERAZINES; SEROTONIN UPTAKE INHIBITORS; TETRABENAZINE;

MUS;

EID: 71049188579     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2009.07.003     Document Type: Article

References (44)

1. Andrews A.M., and Murphy D.L. Fluoxetine and desipramine selectively attenuate 2′-NH2-MPTP-induced depletions in serotonin and norepinephrine. Eur J Pharmacol 250 (1993) 215-221
2. Ase A.R., Strazielle C., Hebert C., Botez M.I., LaLonde R., Descarries L., et al. Central serotonin system in dystonia musculorum mutant mice: biochemical, autoradiographic and immunocytochemical data. Synapse 37 (2000) 179-193
3. Brouillet E., and Beal M.F. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport 4 (1993) 387-390
4. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 153 (1995) 1714-1723
5. Doetsch F., Garcia-Verdugo J.M., and Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17 (1997) 5046-5061
6. Doetsch F., Caille I., Lim D.A., Garcia-Verdugo J.M., and Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97 (1999) 703-716
7. Erickson J.D., Schafer M.K., Bonner T.I., Eiden L.E., and Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93 (1996) 5166-5171
8. Everse J., and Coates P.W. Role of peroxidases in Parkinson disease: a hypothesis. Free Radic Biol Med 38 (2005) 1296-1310
9. Foote S.L., Bloom F.E., and Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63 (1983) 844-914
10. Franklin K.B.J., and Paxinos G.T. The mouse brain in stereotaxic coordinates (1996), Academic Press, London
11. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R., et al. Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359 (1995) 340-349
12. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69 (1997) 1322-1325
13. German D.C., Liang C.L., Manaye K.F., Lane K., and Sonsalla P.K. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. Neuroscience 101 (2000) 1063-1069
14. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 193 (2005) 279-290
15. He X.J., Nakayama H., Dong M., Yamauchi H., Ueno M., Uetsuka K., et al. Evidence of apoptosis in the subventricular zone and rostral migratory stream in the MPTP mouse model of Parkinson disease. J Neuropathol Exp Neurol 65 (2006) 873-882
16. He X.J., Yamauchi H., Uetsuka K., and Nakayama H. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease. Neurotoxicology 29 (2008) 413-420
17. He X.J., Uetsuka K., and Nakayama H. Neural progenitor cells are protected against MPTP by MAO-B inhibitors. Neurotoxicology 29 (2008) 1141-1146
18. Hill M.P., Ravenscroft P., McGuire S.G., Brotchie J.M., Crossman A.R., Rochat C., et al. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: mediation by D2, not D3, dopamine receptors. Mov Disord 21 (2006) 2090-2095
19. Hoglinger G.U., Rizk P., Muriel M.P., Duyckaerts C., Oertel W.H., Caille I., et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7 (2004) 726-735
20. Inazu M., Takeda H., and Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 84 (2003) 43-52
21. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82 (1985) 2173-2177
22. Lange K.W., Kornhuber J., and Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 21 (1997) 393-400
23. Liu Y., and Edwards R.H. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20 (1997) 125-156
24. Nirenberg M.J., Chan J., Liu Y., Edwards R.H., and Pickel V.M. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16 (1996) 4135-4145
25. Park S.W., Kim S.H., Park K.H., Kim S.D., Kim J.Y., Baek S.Y., et al. Preventive effect of antioxidants in MPTP-induced mouse model of Parkinson's disease. Neurosci Lett 363 (2004) 243-246
26. Pifl C., Giros B., and Caron M.G. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium. J Neurosci 13 (1993) 4246-4253
27. Przedborski S., and Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 991 (2003) 189-198
28. Reinhard Jr. J.F., Daniels A.J., and Viveros O.H. Potentiation by reserpine and tetrabenazine of brain catecholamine depletion by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) in the mouse; evidence for subcellular sequestration as basis for cellular resistance to the toxicant. Neurosci Lett 90 (1988) 349-353
29. Rommelfanger K.S., Weinshenker D., and Miller G.W. Reduced MPTP toxicity in noradrenaline transporter knockout mice. J Neurochem 91 (2004) 1116-1124
30. Russ H., Staust K., Martel F., Gliese M., and Schomig E. The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 8 (1996) 1256-1264
31. Schapira A.H. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 9 (2002) 7-14
32. Schroeter S., Apparsundaram S., Wiley R.G., Miner L.H., Sesack S.R., and Blakely R.D. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 420 (2000) 211-232
33. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 134 (2005) 57-66
34. Smith H.R., Beveridge T.J.R., and Porrino L.J. Distribution of norepinephrine transporters in the non-human primate brain. Neuroscience 138 (2006) 703-714
35. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α. FASEB J 20 (2006) 670-682
36. Staal R.G., and Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 293 (2000) 336-342
37. Stephans S.E., Miller G.W., Levey A.I., and Greenamyre J.T. Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology 23 (2002) 569-580
38. Sur C., Betz H., and Schloss P. Immunocytochemical detection of the serotonin transporter in rat brain. Neuroscience 73 (1996) 217-231
39. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94 (1997) 9938-9943
40. Vila M., and Przedborski S. Targeting programmed cell death neurodegenerative diseases. Nat Rev Neurosci 4 (2003) 365-375
41. Wakayama K., Ohtsuki S., Takanaga H., Hosoya K., and Terasaki T. Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neurosci Res 44 (2002) 173-180
42. Weihe E., and Eiden L.E. Chemical neuroanatomy of the vesicular amine transporters. FASEB J 14 (2000) 2435-2449
43. Yokoyama H., Takagi S., Watanabe Y., Kato H., and Araki T. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm 115 (2008) 831-845
44. Zusso M., Debetto P., Guidolin D., Barbierato M., Manev H., and Giusti P. Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochem Pharmacol 76 (2008) 391-403